Head and neck rhabdomyosarcoma (HNRMS) is the most common soft-tissue sarcoma in children. The review reports that roughly 30–40% of pediatric rhabdomyosarcoma cases arise in the head and neck region. Because of the dense concentration of critical structures in the head and neck, HNRMS presents specific diagnostic and therapeutic challenges for pediatric otolaryngology teams.
Anatomical complexity in this region contributes to difficulties in early recognition and complete local control. The review frames HNRMS as a disease in which tumor site, histologic subtype, and molecular characteristics are central determinants of prognosis and treatment planning.
Recent advances in molecular pathology have significantly influenced risk stratification in rhabdomyosarcoma. The identification of FOXO1 fusion status is described as a key prognostic marker. Determination of fusion status and other molecular features allows more accurate prognostic categorization and guides individualized treatment strategies.
The review emphasizes that molecular heterogeneity among tumors underlies differences in clinical behavior and treatment response. Precise histopathological and molecular diagnosis is therefore essential to inform multidisciplinary decision-making.
Modern imaging modalities have improved diagnostic precision and the assessment of local tumor extent in HNRMS. In particular, magnetic resonance imaging (MRI) and PET-based assessment are highlighted as important tools for delineating tumor boundaries, evaluating local invasion, and assisting staging and treatment planning.
The review stresses the value of integrating imaging findings with histopathological and molecular data to form a complete diagnostic picture prior to initiating therapy.
Current management of pediatric HNRMS relies on multimodal therapy that combines systemic chemotherapy with conservative surgery and radiotherapy. The review notes that adopting this combined approach has improved survival outcomes while aiming to limit treatment-related morbidity.
Proton beam radiotherapy is singled out as a contemporary radiotherapeutic modality that can reduce long-term morbidity compared with conventional techniques, particularly relevant in the pediatric head and neck setting where minimizing late effects on developing tissues is critical.
Conservative surgical approaches, when feasible, are used to preserve function and appearance while systemic chemotherapy addresses micrometastatic disease. The review underlines individualized treatment planning within multidisciplinary teams to balance oncologic control and functional outcomes.
Prognosis in pediatric HNRMS is strongly influenced by tumor location. The review summarizes that orbital tumors are associated with favorable outcomes. In contrast, parameningeal lesions continue to present substantial therapeutic difficulties because they are often diagnosed later and lie adjacent to critical neurovascular structures, complicating resection and radiotherapy.
Tumor histology and molecular characteristics, including fusion status, further modify risk and expected outcomes across different anatomical subsites.
Survivorship considerations are a growing focus in the management of pediatric HNRMS. The review highlights several long-term complications encountered by survivors, including craniofacial deformities, endocrine dysfunction, hearing impairment, and the risk of secondary malignancies.
Because many affected children receive multimodal treatment during periods of growth and development, long-term monitoring and multidisciplinary follow-up are emphasized to detect and manage late effects, support rehabilitation, and preserve quality of life.
The authors stress that early recognition, accurate histopathological and molecular diagnosis, and individualized multidisciplinary treatment are essential to optimize survival and reduce long-term morbidity in HNRMS. Otolaryngologists play a central role in the diagnosis, local management, and coordination of care within multidisciplinary pediatric oncology teams.
Multidisciplinary collaboration is particularly important for anatomically complex tumors in the head and neck, where decisions about timing and extent of surgery, radiotherapy modality, and systemic therapy must be carefully balanced against functional preservation.
The review notes ongoing developments in targeted therapy and expanded use of proton radiotherapy as promising avenues that may further improve oncologic outcomes and quality of life for children with HNRMS. While the review summarizes these areas as important directions, it does not provide detailed trial results or specific new agents within the text.
Overall, the review integrates recent molecular, diagnostic, and therapeutic advances from an otolaryngological perspective and emphasizes both survival outcomes and long-term quality-of-life considerations for pediatric patients with head and neck rhabdomyosarcoma.